NEW YORK – Gestalt Diagnostics said today that it has entered two strategic collaborations for cancer pathology testing.
The firm said that it is collaborating with Westminster, Colorado-based Flagship Biosciences to develop an integrated workflow that gives pathologists access to Flagship's analysis services for digital images to support PD-L1 testing.
In a separate announcement, Gestalt said that it has entered a strategic partnership with Hamburg, Germany-based MindPeak to develop an integrated workflow for pathologists to instantaneously send regions of interest to MindPeak's image analysis services. MindPeak's services support evaluation of the ER, PR, and Ki-67 biomarkers for breast cancer diagnosis.
Financial and other terms of the collaborations were not disclosed.   Â
The relationship with Flagship and "resulting automated and streamlined workflow for PD-L1 cases is another step forward in our digital platform," Gestalt COO and Chief Strategy Officer Lisa-Jean Clifford said in a statement. "This new relationship is giving pathologists access to the automation and tools that will continue to increase their efficiency, minimizing the manual steps in their case work."
Gestalt said that the companies aim to provide a more efficient diagnostic process by engaging in a shared service to add Flagship's computational services to Gestalt's PathFlow digital pathology enterprise software platform.
Gestalt will work to integrate Flagship's machine learning and artificial intelligence tools to enable cancer marker detection, Clifford said.
The firms anticipate that users of Gestalt's PathFlow will be able to directly request PD-L1 image analysis service through a computer interface. A PD-L1 report and images will be returned and loaded into the case file for final review, Gestalt said.
By integrating with MindPeak, Gestalt is giving pathologists the ability "to select regions of interest on a digital image, automatically send that to MindPeak, and receive their annotated results back in real-time," Clifford said.